Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

NYU Langone Health

Overview

This study evaluated differences between men and women in the presentation, management and outcome of heart attacks within the GUSTO V study.

The Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO) V trial examined a large, contemporary cohort of women and men with ST elevation myocardial infarction (STEMI) treated with fibrinolytic therapy. The objective of the present study was to evaluate sex differences in presentation, management and outcome in GUSTO V.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Myocardial Infarction

Interventions

fibrinolytic therapy or combination reduced fibrinolytic therapyDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * inclusion into GUSTO V Exclusion Criteria: * lack of availability of data (database study)

Locations (1)

NYU School of Medicine

New York, New York, United States

Outcomes

Primary Outcomes

Primary Outcome

All cause mortality at 30 days after randomization.

Time frame: 30 days

Secondary Outcomes

Incidence of myocardial reinfarction as evidenced by new electrocardiographic changes or elevation in cardiac enzyme levels with recurrent chest pain within 7 days, bleeding, stoke, intracranial hemorrhage (ICH), and complications of MI.

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.